Accrued
expenses included the following:
| | | | | | | | | |
| |
|
March 31,
|
|
|
December 31,
|
|
| |
|
2025
|
|
|
2024
|
|
|
Incentive and other compensation costs
|
|
$ |
600,614 |
|
|
|
650,768 |
|
|
Clinical trial costs
|
|
|
316,731 |
|
|
|
354,762 |
|
|
Accrued interest
|
|
|
147,275 |
|
|
|
44,525 |
|
|
Director fees
|
|
|
71,250 |
|
|
|
70,000 |
|
|
Other
|
|
|
34,418 |
|
|
|
30,994 |
|
|
Accrued expenses
|
|
$
|
1,170,288 |
|
|
|
1,151,049 |
|
|